The purpose of this study is assess the safety and tolerability of AB102 and characterize the pharmacokinetics (PK) profile of AB102 after single and multiple ascending oral dose(s).
Age range
18 Years – 55 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Number of participants experiencing Adverse Events (AEs)
Timeframe: Up to 49 days
Maximum observed plasma concentration (Cmax) for SAD and MAD Parts
Timeframe: Up to 28 days
Time to attain maximum observed plasma concentration (tmax) for SAD and MAD Parts
Timeframe: Up to 28 days
Terminal elimination half-life (t1/2) for SAD Part
Timeframe: Up to 28 days
Area under the plasma concentration-time curve from time 0 to last sample (AUClast) for SAD and MAD Parts
Timeframe: Up to 28 days
Area under the plasma concentration-time curve from time 0 to 24 hours (AUC0-24h) for SAD Part
Timeframe: Up to 28 days
Area under the plasma concentration-time curve from time 0 to infinity (AUCinf) for SAD Part
Timeframe: Up to 28 days
Area under the plasma concentration-time curve over a dosing interval (AUC0-tau) for MAD Part
Timeframe: Up to 28 days
Accumulation ratio (Racc(Cmax))for MAD Part
Timeframe: Up to 28 days
Accumulation ratio(Racc(AUCtau)) for MAD Part
Timeframe: Up to 28 days